{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-166543","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.101955+00:00","generated_at":"2026-06-14T01:21:15.516656+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Spero Therapeutics appoints Sath Shukla as CEO, Mahadevia becomes Chairman","bullets":["CEO Ankit Mahadevia steps down effective Aug 1, 2023; becomes Chairman of the Board.","CFO Satyavrat 'Sath' Shukla appointed CEO and President, also joins Board.","Stephen DiPalma appointed Interim CFO, effective Aug 1, 2023.","Chairman Milind Deshpande steps down but remains director; Patrick Vink named Lead Independent Director.","Mahadevia to receive $54k/month consulting fee through Jan 2024, then $310/hour through July 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-166543","json":"https://secwatch.observer/filing/0001193125-23-166543.json","markdown":"https://secwatch.observer/filing/0001193125-23-166543.md","text":"https://secwatch.observer/filing/0001193125-23-166543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523166543/0001193125-23-166543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523166543/d509385d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T01:21:15.516656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ac6d6d975","claim":"Ankit Mahadevia departed as Chief Executive Officer and President at Spero Therapeutics, Inc..","evidence_excerpt":"Ankit Mahadevia, M.D., the Company’s Chief Executive Officer and President, determined to step down from that role, effective as of August 1, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523166543/0001193125-23-166543-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"},{"claim_id":"616a9eee1a","claim":"Satyavrat Shukla was appointed as Chief Executive Officer and President at Spero Therapeutics, Inc..","evidence_excerpt":"Satyavrat Shukla, the Company’s current Chief Financial Officer and Treasurer, was appointed by the Board to serve as Chief Executive Officer and President of the Company and as a member of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523166543/0001193125-23-166543-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"},{"claim_id":"717f1c23cc","claim":"Stephen J. DiPalma was appointed as Interim Chief Financial Officer and Treasurer at Spero Therapeutics, Inc..","evidence_excerpt":"Stephen J. DiPalma to be the Company’s Interim Chief Financial Officer and Treasurer to succeed Mr. Shukla","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523166543/0001193125-23-166543-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer and Treasurer"}],"fact_type":"executive_change"},{"claim_id":"b978ccc361","claim":"Ankit Mahadevia was appointed as Chairman of the Board at Spero Therapeutics, Inc..","evidence_excerpt":"Dr. Mahadevia will serve as a consultant to the Company and will continue to serve as a member of the Company’s Board of Directors (the “Board”) and will assume the role of Chairman of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523166543/0001193125-23-166543-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assume"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}